压缩式吸入器雾化吸入布地奈德治疗5岁以下儿童哮喘临床观察

Clinical study on inhalation of budesonid with nebulizer in the treatment of children with asthma

目的观察经压缩式吸入器吸入布地奈德雾化悬液治疗幼儿哮喘的临床疗效及适用性。方法采用多中心、开放方法,选择≤5岁、临床确诊为支气管哮喘、症状未完全控制的61例患儿进行吸入治疗。入选者使用哮喘日记的形式每日对哮喘症状分别进行日间和夜间评分,每周随访1次,总疗程为6周。分别对治疗第1～6周哮喘症状评分进行控制评估,并对周-周之间的评分及控制评估行两两比较。结果症状评分第2～6周各周与第1周比较,差异有统计学意义(P均<0.05);第2～6周之间周-周比较差异无统计学意义;连续应用2周以后患儿的完全控制比例呈明显上升达56.8%,并维持至疗程结束;整个疗程中患儿均无明显不良反应。结论经压缩式雾化吸入器吸入布地奈德雾化悬液治疗5岁以下哮喘儿童,可显著提高患儿的哮喘控制率,具有良好的安全性,依从性好,值得在儿科临床中应用。

Objectives To evaluate the clinical effects of inhalation of budesonid with nebulizer via jet （NE-C28） on children younger than 5 years old with asthma. Methods Budesonid were given with nebulizer for 6 weeks in 61 children （aged 5-62 months） with recurrent wheeze. Symptomatic score during daytime and night were recorded by the patients each day. Patients were followed-up and the scores were assessed every week after treatment. The differences on symptomatic score every week, between first week and 2, 3, 4, 5, 6 week after treatment were analyzed. Results The differences in the symptom score were significant between the first week and every week after treatment （P 〈 0.05）, while the difference in every week after treatment were not significant. The clinical effective rates increased significantly after 2 weeks＇ treatment （56.8%）, and reached to 68.2% in week 6. There were no significant side-effects reported by the patients during the period of treatment. Conclusions Inhalation of budesonid with nebulizer is effective for alleviating clinical symptom of asthma and it is really a safe, well-compliance therapeutic approach for children younger than 5 years old with asthma.